2025
Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma
Yang L, Pham K, Xi Y, Wu Q, Liu D, Robertson K, Liu C. Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma. PLOS ONE 2025, 20: e0317401. PMID: 39841705, PMCID: PMC11753693, DOI: 10.1371/journal.pone.0317401.Peer-Reviewed Original ResearchConceptsGlypican-3Hepatocellular carcinomaCAR-NKNatural killerCell linesCAR-NK therapyCAR-NK cellsTreatment of hepatocellular carcinomaNK cell lineAnti-tumor effectsCancer-related mortalitySuppressed tumor growthPrimary liver cancerInfluence therapeutic outcomesCells in vitroHepatocellular carcinoma treatmentHepG2 cells in vitroNK92MI cellsImmunotherapy strategiesNSG miceImmunotherapy targetOncofetal glycoproteinTherapy resistanceImprove patient outcomesPoor prognosis
2024
Molecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinoma
Santana J, Shewarega A, Nam D, Duncan J, Madoff D, Hyder F, Coman D, Chapiro J. Molecular MRI of T-cell immune response to cryoablation in immunologically hot vs. cold hepatocellular carcinoma. JHEP Reports 2024, 7: 101294. PMID: 40028344, PMCID: PMC11870164, DOI: 10.1016/j.jhepr.2024.101294.Peer-Reviewed Original ResearchT cell infiltrationHepatocellular carcinomaRadiological-pathological correlationImaging mass cytometryImmune responseT1-weighted MRITumor-infiltrating CD8+ T lymphocytesAnti-tumor immune responseCD8+ T lymphocytesIncreased T lymphocyte infiltrationImaging biomarkersNon-immunogenic tumorsSystemic lymph nodesT lymphocyte infiltrationMurine tumor modelsImmune cell typesLocal tumor therapyPrimary liver cancerNon-invasive imaging biomarkerTesla MRI scannerInduce liver cirrhosisImmunogenic tumorsLocoregional therapySystemic immunotherapyHCC lesions
2023
Liver cancer risk quantification through an artificial neural network based on personal health data
Ataei A, Deng J, Muhammad W. Liver cancer risk quantification through an artificial neural network based on personal health data. Acta Oncologica 2023, 62: 495-502. PMID: 37211681, DOI: 10.1080/0284186x.2023.2213445.Peer-Reviewed Original ResearchConceptsNational Health Interview SurveyLiver cancer riskHealth dataCancer riskHealth Interview SurveyHepatocellular carcinomaPersonal health dataHigh-risk populationLiver cancerInterview SurveyReceiver operating characteristic curveArea under the receiver operating characteristic curveCancer-related deathsPrimary liver cancerHealthOvarian cancerTherapeutic optionsMalignant diseaseTest cohortEarly detectionAggressive progressionRiskCancerCharacteristic curveLiverHepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries
An L, Zheng R, Zhang S, Chen R, Wang S, Sun K, Lu L, Zhang X, Zhao H, Zeng H, Wei W, He J. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries. HepatoBiliary Surgery And Nutrition 2023, 0: 0-0. PMID: 36860251, PMCID: PMC9944524, DOI: 10.21037/hbsn-21-75.Peer-Reviewed Original ResearchPopulation-based cancer registriesAge-standardized ratesOverall age-standardized rateIncidence of HCCIntrahepatic cholangiocarcinomaHepatocellular carcinomaICC incidenceHCC incidenceCancer RegistryNationwide incidencePopulation-based cancer registry dataHepatitis B virus (HBV) vaccinationB virus vaccinationHepatitis B vaccinationLiver cancer incidenceEnd Results ProgramPopulation-based registryPrimary liver cancerCancer registry dataLiver cancer casesHealthy lifestyle promotionLiver cancer controlLiver cancer subtypesOverall Hepatocellular carcinomaB vaccinationDisparities in stage at diagnosis for liver cancer in China
Shan T, Ran X, Li H, Feng G, Zhang S, Zhang X, Zhang L, Lu L, An L, Fu R, Sun K, Wang S, Chen R, Li L, Chen W, Wei W, Zeng H, He J. Disparities in stage at diagnosis for liver cancer in China. Journal Of The National Cancer Center 2023, 3: 7-13. PMID: 39036312, PMCID: PMC11256694, DOI: 10.1016/j.jncc.2022.12.002.Peer-Reviewed Original ResearchLiver cancerStage IIIStage distributionHospital-based studyProportion of patientsLiver Cancer stagePrimary liver cancerCancer control policiesCancer awarenessCancer stageTreatment strategiesFamily historyStudy populationStage ISocioeconomic populationsCancerLogistic regressionPatientsDiagnosisEarly detectionHigher proportionDifferent populationsPopulationProportionHospitalMitochondrial calcium signaling in cholangiocarcinoma
Loyola-Machado A, Guerra M, Nathanson M. Mitochondrial calcium signaling in cholangiocarcinoma. Hepatoma Research 2023, 9: null-null. DOI: 10.20517/2394-5079.2023.28.Peer-Reviewed Original ResearchPrimary liver cancerNew pharmacological agentsPathogenesis of cholangiocarcinomaMitochondrial Ca2Liver cancerCholangiocarcinomaPharmacological agentsIntracellular Ca2Molecular alterationsDruggable targetsER-mitochondrial contact sitesCancer cellsKey regulatory moleculesMetabolic reprogramingReceptor familyMitochondrial healthMitochondrial calciumEnergy metabolismCell deathPathways of interestLatest findingsTreatmentCa2Regulatory moleculesContact sites
2022
Pathogenesis to management of hepatocellular carcinoma
Da B, Suchman K, Lau L, Rabiee A, He A, Shetty K, Yu H, Wong L, Amdur R, Crawford J, Fox S, Grimaldi G, Shah P, Weinstein J, Bernstein D, Satapathy S, Chambwe N, Xiang X, Mishra L. Pathogenesis to management of hepatocellular carcinoma. Genes & Cancer 2022, 13: 72-87. PMID: 36533190, PMCID: PMC9746873, DOI: 10.18632/genesandcancer.226.Peer-Reviewed Original ResearchHepatocellular carcinomaCommon primary liver cancerEarly-stage hepatocellular carcinomaLiver-directed therapiesPathogenesis of HCCPrimary liver cancerMetastatic hepatocellular carcinomaViable animal modelAdvanced diseaseLiver resectionSystemic therapyPoor prognosisRisk factorsHCC managementHistological classificationLiver cancerNew therapiesAnimal modelsTherapyTissue samplingRelevant biomarkersAlcohol useMolecular targetsCarcinomaPathogenesis
2021
Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver
Oestmann PM, Wang CJ, Savic LJ, Hamm CA, Stark S, Schobert I, Gebauer B, Schlachter T, Lin M, Weinreb JC, Batra R, Mulligan D, Zhang X, Duncan JS, Chapiro J. Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver. European Radiology 2021, 31: 4981-4990. PMID: 33409782, PMCID: PMC8222094, DOI: 10.1007/s00330-020-07559-1.Peer-Reviewed Original ResearchConceptsNon-HCC lesionsHepatocellular carcinomaHCC lesionsAtypical imagingGrading systemLI-RADS criteriaAtypical imaging featuresPrimary liver cancerTypical hepatocellular carcinomaAtypical hepatocellular carcinomaContrast-enhanced MRISensitivity/specificityLiver transplantMethodsThis IRBRetrospective studyLiver malignanciesImaging featuresLiver cancerAtypical featuresConclusionThis studyLesionsMRIClinical applicationCarcinomaImage-based diagnosis
2020
Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression
Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Advances In Cancer Research 2020, 149: 321-387. PMID: 33579427, PMCID: PMC8800451, DOI: 10.1016/bs.acr.2020.10.005.Peer-Reviewed Original ResearchConceptsIntrahepatic cholangiocarcinomaMalignant progressionCommon primary liver cancerPrimary hepatic malignancyPrimary liver cancerStandard of careHigh mortality rateICCA developmentMalignant aggressivenessHepatic malignanciesHepatobiliary cancersTumor immunobiologyDesmoplastic stromaHepatocellular carcinomaLiver cancerMortality rateTherapy resistanceEpithelial cancersDeleterious roleCell originCancerReactive microenvironmentMicroenvironmental factorsProgressionManagement optionsCholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology & Hepatology 2020, 17: 557-588. PMID: 32606456, PMCID: PMC7447603, DOI: 10.1038/s41575-020-0310-z.Peer-Reviewed Original ResearchConceptsPrimary liver cancerExpert consensus statementCancer-related deathCell of originBiliary malignant tumorsStudy of CholangiocarcinomaGastrointestinal malignanciesHistological confirmationAvailable therapiesBiliary treeNew diagnostic toolsSilent presentationPatient outcomesConsensus statementMalignant tumorsLiver cancerCholangiocarcinomaAggressive natureAlarming mortalityCurrent diagnosisMolecular alterationsNon-invasive approachTumorsDiagnostic toolTherapySurveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
Torres M, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers 2020, 12: 1422. PMID: 32486355, PMCID: PMC7352281, DOI: 10.3390/cancers12061422.Peer-Reviewed Original ResearchLiver diseaseHepatocellular carcinomaRisk factorsHCC surveillanceNAFLD patientsNon-alcoholic fatty liver diseasePrevalence of HCCFrequent primary liver cancerNon-alcoholic fatty liverNon-cirrhotic NAFLDNon-cirrhotic subjectsCause of cirrhosisTreatment of HBVChronic liver diseaseFatty liver diseasePrimary liver cancerCancer-related deathMain risk factorsGood clinical judgmentEarly HCC detectionDeaths/yearNew screening toolNAFLD epidemicHCV infectionLiver ultrasonographyGenomics and Interventional Oncology in Primary Liver Cancer
Slovak R, Dendy Case M, Kim H. Genomics and Interventional Oncology in Primary Liver Cancer. Digestive Disease Interventions 2020, 04: 053-059. DOI: 10.1055/s-0040-1708533.Peer-Reviewed Original ResearchPrimary liver cancerLiver cancerInterventional oncologyForms of malignancyOncologic careInterventional oncologistsIntrahepatic cholangiocarcinomaHepatocellular carcinomaIndividual tumorsCancerPrecision medicineOncologyPersonalized medicineRadiogenomics researchRadiomicsMedicineCholangiocarcinomaCarcinomaMalignancyOncologistsTumorsCare
2019
Molecular Pathogenesis: From Inflammation and Cholestasis to a Microenvironment-Driven Tumor
Milani E, Strazzabosco M, Fabris L, Cadamuro M. Molecular Pathogenesis: From Inflammation and Cholestasis to a Microenvironment-Driven Tumor. 2019, 167-182. DOI: 10.1007/978-3-030-22258-1_12.Peer-Reviewed Original ResearchTumor reactive stromaIntrahepatic cholangiocarcinomaReactive stromaTumor-infiltrating lymphocytesPrimary liver cancerTumor-associated macrophagesCancer-associated fibroblastsMalignant bile ductPro-invasive functionMain stromal cell typesBiliary lesionsProgenitor stem cellsBile ductChronic inflammationStromal cell typesPortal tractsTumor overgrowthLiver cancerPathogenetic sequenceMalignant transformationParacrine factorsTumor microenvironmentCholestasisOncogenic effectsInflammation
2018
Racial Disparities and Sociodemographic Differences in Incidence and Survival Among Pediatric Patients in the United States With Primary Liver Cancer
Nautsch F, Ludwig J, Xing M, Johnson K, Kim H. Racial Disparities and Sociodemographic Differences in Incidence and Survival Among Pediatric Patients in the United States With Primary Liver Cancer. Journal Of Clinical Gastroenterology 2018, 52: 262-267. PMID: 28617762, DOI: 10.1097/mcg.0000000000000833.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsBlack or African AmericanCarcinoma, HepatocellularChildChild, PreschoolFemaleHealth Services AccessibilityHealth Status DisparitiesHepatoblastomaHumansIncidenceInfantInfant, NewbornLiver NeoplasmsMaleProportional Hazards ModelsRacial GroupsSEER ProgramSurvival RateTime FactorsUnited StatesWhite PeopleYoung AdultConceptsPrimary liver cancerOverall survivalHepatocellular carcinomaAfrican American childrenPediatric patientsLiver cancerEnd Results cancer registry dataUniversal health care accessAmerican childrenCancer registry dataHealth care accessTreatment-related informationAge of diagnosisFactors affecting outcomePopulation database studyCare accessSociodemographic differencesMedian ageRacial disparitiesRegistry dataPediatric populationHepatoblastomaDecreased survivalPatientsDatabase study
2017
Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview
Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. Gene Expression 2017, 18: 31-50. PMID: 29070148, PMCID: PMC5860940, DOI: 10.3727/105221617x15088670121925.Peer-Reviewed Original ResearchConceptsMajority of patientsPrimary liver cancerCancer-related deathPotential prognostic relevanceDevelopment of metastasesPro-oncogenic pathwaysNovel druggable targetsMechanism of actionCholangiocarcinoma invasivenessMesenchymal-like phenotypeDevastating malignancyCurative treatmentMolecular mechanismsPoor prognosisPrognostic relevancePrimary tumorBiliary epitheliumLiver cancerUseful biomarkerAbnormal activationCCA cell invasionMost carcinomasCCA cellsTumor microenvironmentCholangiocarcinoma
2016
Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma
Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Research 2016, 76: 4775-4784. PMID: 27328733, PMCID: PMC4987167, DOI: 10.1158/0008-5472.can-16-0188.Peer-Reviewed Original ResearchMeSH KeywordsActive Transport, Cell NucleusAnimalsAntineoplastic Agents, PhytogenicBile Duct NeoplasmsBlotting, WesternCell Line, TumorCell ProliferationCholangiocarcinomaHumansMiceMice, SCIDNeoplasm InvasivenessNeoplasm MetastasisPaclitaxelS100 Calcium-Binding Protein A4SumoylationXenograft Model Antitumor AssaysConceptsLow-dose paclitaxelNuclear S100A4Nuclear expressionSCID mouse xenograft modelPrimary liver cancerLocal tumor growthEGI-1 cellsCandidate therapeutic targetMouse xenograft modelMMP-9 secretionCholangiocarcinoma cell linesCholangiocarcinoma invasivenessLung disseminationMT1-MMP expressionCalcium binding proteinDismal prognosisRate of proliferationMetastatic spreadLiver cancerTumor massPaclitaxel treatmentXenograft modelTherapeutic targetTreatment opportunitiesMetastatic progression
2015
Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?
Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma? Journal Of Clinical Medicine 2015, 4: 2028-2041. PMID: 26703747, PMCID: PMC4693158, DOI: 10.3390/jcm4121958.Peer-Reviewed Original ResearchMesenchymal transitionAbundant stromal reactionEarly metastatic behaviorPrimary liver cancerEMT-like changesPotential therapeutic targetPro-invasive phenotypeSpecific disease mechanismsDismal prognosisBile ductChronic inflammationEMT biomarkersEpithelial malignanciesStromal reactionLiver cancerTumor stromaTherapeutic targetCholangiocarcinomaNew biomarkersTumor metastatizationMetastatic behaviorCCA cellsTherapeutic opportunitiesTumor microenvironmentStromal cells
2013
Percutaneous therapies of hepatocellular carcinoma—an update
Chapiro J, Geschwind JF. Percutaneous therapies of hepatocellular carcinoma—an update. Chinese Clinical Oncology 2013, 2: 36-36. PMID: 25841915, DOI: 10.3978/j.issn.2304-3865.2013.07.04.Peer-Reviewed Original ResearchIntra-arterial therapyHepatocellular carcinomaSpecific therapeutic algorithmsAvailable clinical evidenceEarly-stage diseaseIntra-arterial approachEnd-stage diseaseLocal tumor controlPrimary liver cancerTreatment of patientsTherapeutic algorithmEthanol ablationTransarterial chemoembolizationClinical evidencePatient groupTumor controlPercutaneous techniquesRadiofrequency ablationSuch therapyTherapeutic spectrumAblative techniquesPercutaneous therapyLiver cancerSystemic toxicityTherapyMouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target
Saborowski A, Saborowski M, Davare M, Druker B, Klimstra D, Lowe S. Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target. Proceedings Of The National Academy Of Sciences Of The United States Of America 2013, 110: 19513-19518. PMID: 24154728, PMCID: PMC3845141, DOI: 10.1073/pnas.1311707110.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Duct NeoplasmsBile Ducts, IntrahepaticCell Line, TumorCholangiocarcinomaDisease Models, AnimalGene Expression Regulation, NeoplasticGene Transfer TechniquesGenes, p53Genetic TherapyLiver NeoplasmsMiceMutationOncogene Proteins, FusionProto-Oncogene Proteins p21(ras)RetroviridaeRNA InterferenceConceptsMouse model of intrahepatic cholangiocarcinomaIntrahepatic cholangiocarcinomaTherapeutic targetPrimary liver cancerHuman intrahepatic cholangiocarcinomaROS1 fusionsTumor typesAntitumor effectPreclinical toolGenetic alterationsFusion oncogeneBiliary treeMouse modelLiver cancerHepatic parenchymaCholangiocarcinomaFusion geneTumorICC developmentHuman diseasesIntraarterial therapies for primary liver cancer: state of the art
Chapiro J, Tacher V, Geschwind JF. Intraarterial therapies for primary liver cancer: state of the art. Expert Review Of Anticancer Therapy 2013, 13: 1157-1167. PMID: 24099626, DOI: 10.1586/14737140.2013.845528.Peer-Reviewed Original ResearchConceptsPrimary liver cancerTreatment of patientsIntraarterial therapyHepatocellular carcinomaLiver cancerIntermediate-stage diseaseOfficial treatment guidelinesAvailable clinical evidenceEffective local tumor controlLocal tumor controlReduced systemic toxicityIntraarterial approachStage diseaseTransarterial chemoembolizationTreatment guidelinesClinical evidenceHepatic malignanciesTumor controlSystemic toxicityTherapyScientific rationalePatientsCancerTreatmentChemoembolization
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply